Bradley Foster & Sargent Inc. CT Boosts Stock Position in AxoGen, Inc. (NASDAQ:AXGN)

Bradley Foster & Sargent Inc. CT lifted its position in AxoGen, Inc. (NASDAQ:AXGN) by 3.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 84,153 shares of the medical equipment provider’s stock after acquiring an additional 2,989 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in AxoGen were worth $1,387,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in AXGN. JPMorgan Chase & Co. grew its position in shares of AxoGen by 2,912.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 549,000 shares of the medical equipment provider’s stock worth $7,697,000 after acquiring an additional 530,775 shares in the last quarter. Parkman Healthcare Partners LLC acquired a new position in AxoGen during the 3rd quarter valued at approximately $5,789,000. FMR LLC boosted its position in AxoGen by 743.1% during the 3rd quarter. FMR LLC now owns 178,957 shares of the medical equipment provider’s stock valued at $2,509,000 after purchasing an additional 157,730 shares during the period. Eagle Asset Management Inc. acquired a new position in AxoGen during the 3rd quarter valued at approximately $1,728,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in AxoGen by 66.3% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 308,686 shares of the medical equipment provider’s stock valued at $4,328,000 after purchasing an additional 123,118 shares during the period. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Stock Down 2.7 %

Shares of AxoGen stock opened at $18.00 on Friday. The business’s fifty day moving average price is $17.29 and its two-hundred day moving average price is $14.77. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The company has a market capitalization of $792.18 million, a P/E ratio of -56.25 and a beta of 1.00. AxoGen, Inc. has a 1-year low of $5.55 and a 1-year high of $19.19.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group boosted their price objective on AxoGen from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, February 3rd.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.